SC issues notice on PIL seeking action against doctors who do not prescribe generic medicines

New Delhi : The Supreme Court on Friday issued notice on a PIL seeking disciplinary actions against doctors who fail to prescribe generic medicines.

A bench comprising Chief Justice of India D.Y. Chandrachud, Justices J.B. Pardiwala and Manoj Misra sought response from the Centre, all state governments, Ethics and Medical Registration Board (erstwhile Medical Council of India) and others in the matter.

Advocate K.C. Jain, the petitioner, apprised the bench that regulations emphasizing the importance of prescribing generic medicines, which were notified back in 2002, remain largely unimplemented in practice.

He said that the Indian Medical Council (Professional Conduct, Etiquette, and Ethics) Regulations, 2002, which highlight the significance of prescribing drugs by their generic names, exist solely within legal frameworks.

The plea said that affordability of medicines is a vital factor that contributes to effective healthcare delivery and the realization of the ‘right to health’.

“Generic drugs, which have the same active ingredients as their branded counterparts but are not marketed under a specific brand name, are often significantly cheaper. The prices of generic medicines (off-patented) can be 50 per cent to 90 per cent lower than those of branded medicines,” stated the petition.

It sought directions to the National Pharmaceuticals Pricing Authority to fix the Maximum Retail Price (MRP) of Non Scheduled formulations and off-patented generic medicines.

“By prescribing generic drugs, healthcare professionals can help alleviate the financial burden on patients and facilitate their access to vital medications,” the plea said.

Related Posts

Over-the-counter sale of cough syrup barred

Following the Drugs Rules amendment, lozenges, pills, and tablets for cough will still be available over the counter; 24 children in M.P. died after consuming adulterated cough syrup last year…

FDA seals Bhiwandi-based cosmetic factory for misleading claims, fake address

Mumbai: On Tuesday, the FDA said it had sealed a cosmetic manufacturing factory in Bhiwandi for allegedly misleading consumers on e-commerce platforms by labelling its products as sulfate-free and paraben-free. The stock…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Over-the-counter sale of cough syrup barred

Over-the-counter sale of cough syrup barred

FDA seals Bhiwandi-based cosmetic factory for misleading claims, fake address

FDA seals Bhiwandi-based cosmetic factory for misleading claims, fake address

Yashoda Medicity’s AI-enabled E- ICU poised to make Quality Critical Care Universal

Yashoda Medicity’s AI-enabled E- ICU poised to make Quality Critical Care Universal

Licences no shield in NDPS cases: HC refuses bail in 1.37 crore tablets seizure

Licences no shield in NDPS cases: HC refuses bail in 1.37 crore tablets seizure

No cough syrups without a doctor’s prescription – New rules announced

No cough syrups without a doctor’s prescription – New rules announced

CSIR-IIIM launches two-month certificate course On cGMP-compliant herbal drug manufacturing

CSIR-IIIM launches two-month certificate course On cGMP-compliant herbal drug manufacturing